Patient characteristics
|
Antimicrobials after iCDI treatment modeled as time dependent variables
|
Antimicrobials after iCDI treatment modeled as time independent variables
|
---|
Risk factor
|
Hazard ratio
|
95% CI
|
Hazard ratio
|
95% CI
|
---|
At admission to the hospital
| | | | |
CDI case status
| | | | |
HO CDI
|
Ref
| |
Ref
| |
COHCFA CDI
|
1.80
|
1.41-2.29
|
1.78
|
1.39-2.27
|
CA CDI
|
1.30
|
0.95-1.80
|
1.25
|
0.91-1.72
|
Number of hospitalizations in previous 60 days
| | | | |
None
|
Ref
| | | |
1
|
1.25
|
0.97-1.61
|
1.27
|
0.99-1.64
|
>1
|
1.40
|
1.04-1.89
|
1.46
|
1.08-1.96
|
Age (per 1 year)
|
1.01
|
1.00-1.02
|
1.01
|
1.00-1.02
|
At the onset or during treatment of iCDI
| | | | |
Gastric acid suppression
|
1.36
|
1.00-1.85
|
1.40
|
1.03-1.90
|
Cumulative fluoroquinolone exposurea
|
1.24
|
1.09-1.41
|
1.42
|
1.25-1.61
|
Following completion of iCDI treatment
| | | | |
High risk antimicrobialb
|
2.95c
|
2.25-3.86
|
1.86
|
1.42-2.42
|
Fluoroquinolone
|
1.56c
|
1.63-2.08
|
0.86
|
0.64-1.15
|
IV vancomycin
|
1.45c
|
1.09-1.92
|
1.05
|
0.80-1.39
|
- iCDI = initial episode of C. difficile infection.
-
aCumulative fluoroquinolone exposure was modeled as a three node spline.
-
bHigh risk antimicrobials included all cephalosporins, clindamycin, and penicillins.
-
cExposure at any time t.